An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
2022-06-29
عنوان الدراسة
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
داعم الدراسة
Bristol-Myers Squibb
دواء الدراسة
NIVOLUMAB IPILIMUMAB
رقم بروتوكول الدراسة
CA209-227
حالة الدراسة
Terminated
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。